Systematic review and network meta‐analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen‐deprivation therapy to reduce risk of fragility fractures

No abstract is available for this paper.

• Publication year

  2018

• Venue

  BJU International

• Publication date

  2018-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bju.14015PMID 28921820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.

  2016cited by this paper
• Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect in Routine Clinical Practice

  2016cited by this paper
• Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials

  2016cited by this paper
• Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

  2015cited by this paper
• Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

  2014cited by this paper
• Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

  2013cited by this paper
• Evidence Synthesis for Decision Making 2

  2013cited by this paper
• A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.

  2013cited by this paper
• RTOG 0518: Randomized Phase III Trial to Evaluate Zoledronic Acid for Prevention of Osteoporosis and Associated Fractures in Prostate Cancer Patients

  2013cited by this paper
• Safety concerns with the long-term management of osteoporosis

  2013cited by this paper
• Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis.

  2013cited by this paper
• NCCN Task Force Report: Bone Health In Cancer Care.

  2013cited by this paper
• Evidence Synthesis for Decision Making Inconsistency in Networks of Evidence Based on Randomized Controlled Trials.

  2013cited by this paper
• Demystifying trial networks and network meta-analysis

  2013cited by this paper
• Evidence Synthesis for Decision Making 4

  2013cited by this paper
• Osteoporosis in men: an Endocrine Society clinical practice guideline.

  2012cited by this paper
• Zoledronic acid

  2012cited by this paper
• The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer

  2012cited by this paper
• Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons

  2011cited by this paper
• A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.

  2011cited by this paper
• Androgen Deprivation Therapy for Prostate Cancer

  2011cited by this paper
• Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours.

  2011cited by this paper
• Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

  2011cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials

  2011cited by this paper
• Zoledronic-acid

  2011cited by this paper
• Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

  2010cited by this paper
• Adverse Effects of Bisphosphonates

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

  2010cited by this paper
• Long term zoledronic acid during androgen blockade for prostate cancer.

  2010cited by this paper
• Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer

  2009cited by this paper
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

  2009cited by this paper
• Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Androgen deprivation therapy for prostate cancer

  2008cited by this paper
• Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

  2008cited by this paper
• The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

  2007cited by this paper
• Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

  2007cited by this paper
• Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

  2007cited by this paper
• NCCN Task Force Report: Bone Health in Cancer Care.

  2006cited by this paper
• Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

  2006cited by this paper
• Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review.

  2006cited by this paper
• Estimating the mean and variance from the median, range, and the size of a sample

  2005cited by this paper
• Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.

  2004cited by this paper
• Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

  2003cited by this paper
• Skeletal fractures negatively correlate with overall survival in men with prostate cancer.

  2002cited by this paper
• Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

  2001cited by this paper
• WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility

  2000cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper

• Mechanistic Roles of Androgen and Estrogen in Aging and Age-Related Diseases

  2026cites this paper
• The 2024 UK clinical guideline for the prevention and treatment of osteoporosis

  2025cites this paper
• Management of cancer treatment–induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey

  2024cites this paper
• Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

  2024cites this paper
• Management of bone loss due to endocrine therapy during cancer treatment

  2023cites this paper
• Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer

  2022cites this paper
• UK clinical guideline for the prevention and treatment of osteoporosis

  2022cites this paper
• Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer

  2022cites this paper
• Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy

  2022cites this paper
• [Recent advances in the sex steroid hormone action involved in the development of dementia and frailty].

  2022cites this paper
• Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

  2022cites this paper
• Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer

  2022cites this paper
• Hormonally regulated myogenic miR-486 influences sex-specific differences in cancer-induced skeletal muscle defects.

  2021cites this paper
• Radiopharmaceuticals for Bone Metastases.

  2021cites this paper
• Pharmacologically treated diabetes and hospitalization among older Norwegians receiving homecare services from 2009 to 2014: a nationwide register study

  2021cites this paper
• Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea

  2021cites this paper
• Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis

  2021cites this paper
• Cancer Treatment–Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review

  2021cites this paper
• Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer

  2020cites this paper
• A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer.

  2020cites this paper
• Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion

  2020cites this paper
• A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study

  2020cites this paper
• Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer

  2019cites this paper
• Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.

  2019cites this paper
• Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis

  2019cites this paper
• Case of atypical femoral fractures that mimicked the typical imaging findings of prostate cancer‐induced bone metastasis

  2019cites this paper
• Importance of the correct assessment of bone fractures in the clinical management of metastatic castration-resistant prostate cancer treated with radium-223: A case report.

  2019cites this paper
• Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro‐oncologists' opinions and practice

  2018cites this paper
• The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer

  2018cites this paper
• Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures—a study from the fractures and fall injuries in the elderly cohort (FRAILCO)

  2018cites this paper